Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose safety, tolerability, and pharmacokinetics of GIA632 in Japanese healthy adults
jRCT2071250112Phase 1Recruiting
- Sponsor
- Novartis
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing GIA632 arm with Placebo arm (2 arms). Primary endpoint: Safety and tolerability endpoints. Started Dec 2025; status: recruiting.
02
Drugs
GIA632
Beyond the preview
Go deeper on jRCT2071250112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250112.